Progenics Pharmaceuticals, Inc. (PGNX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.44-0.08 (-1.23%)
At close: 4:00 PM EDT
People also watch:
NBIXARRYRIGLPTIESGYP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open6.49
Prev Close6.52
Bid6.01 x 100
Ask6.98 x 300
Day's Range6.40 - 6.67
52wk Range3.61 - 8.37
1y Target EstN/A
Market Cap450.71M
P/E Ratio (ttm)-12.70
Beta2.58
Volume928,106
Avg Vol (3m)1,582,878
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Bloomberg26 days ago

    Valeant’s Relistor Said to Draw Interest of Potential Buyers

    Valeant Pharmaceuticals International Inc.’s Relistor drug has attracted interest from other companies as the beleaguered Canadian firm works to reduce its debt load, people familiar with the matter said....

  • Associated Press27 days ago

    Progenics reports 2Q loss

    The Tarrytown, New York-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Progenics shares have decreased nearly 5 percent ...

  • GlobeNewswire27 days ago

    Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

    On July 19, the Company Announced FDA Approval of RELISTOR ® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Registrational Trial Topline Results Expected Between ...